chloroxine - Profile

What are the generic drug sources for chloroxine and what is the scope of freedom to operate?

Chloroxine is the generic ingredient in one branded drug marketed by Westwood Squibb and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for chloroxine

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for chloroxine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Westwood Squibb	CAPITROL	chloroxine	SHAMPOO;TOPICAL	017594-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Expired US Patents for chloroxine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Westwood Squibb	CAPITROL	chloroxine	SHAMPOO;TOPICAL	017594-001	Approved Prior to Jan 1, 1982

Chloroxine: Patent Landscape and Investment Fundamentals Analysis

Last updated: February 18, 2026

Chloroxine is an antiparasitic and antiseptic agent. It is primarily used in topical formulations to treat skin conditions, including acne and seborrheic dermatitis. The drug's mechanism of action involves chelating essential metal ions required for microbial growth.

What is the current patent status of chloroxine?

The patent landscape for chloroxine is characterized by expired foundational patents covering the compound itself. The original synthesis and therapeutic uses of chloroxine are no longer protected by active intellectual property rights. This has led to a market where generic versions of chloroxine are available.

Patent Type	Status	Expiration Date
Composition of Matter	Expired	N/A
Method of Use	Expired	N/A

While the core patents have lapsed, there may be secondary patents related to specific formulations, delivery systems, or novel therapeutic applications of chloroxine. These secondary patents, if present and active, could offer limited protection and create niche market opportunities.

What is the market size and growth potential for chloroxine?

The market for chloroxine is primarily driven by its use in over-the-counter (OTC) and prescription topical dermatological products. The global market size for acne treatments, a significant segment for chloroxine, was estimated at approximately $9.8 billion in 2023 and is projected to reach $14.7 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.0% [1]. Seborrheic dermatitis treatment market is smaller but also shows steady growth due to the chronic nature of the condition.

Chloroxine's market share within these larger segments is constrained by the availability of numerous alternative treatments, including benzoyl peroxide, salicylic acid, retinoids, and topical antibiotics. Its established safety profile and low cost make it a viable option, particularly in OTC formulations and in regions where access to newer, more expensive treatments is limited.

Growth potential is moderate, primarily linked to the expansion of the overall dermatological market and potential new indications or improved formulations. Significant growth would likely require substantial clinical evidence supporting novel uses or the development of advanced delivery systems that enhance efficacy or patient compliance.

Who are the key players and competitors in the chloroxine market?

The chloroxine market is fragmented due to the absence of strong patent protection on the active pharmaceutical ingredient. Key players are primarily generic manufacturers and formulators of topical dermatological products.

Major competitors offering dermatological treatments that compete with chloroxine include:

• Generic Pharmaceutical Companies: Numerous companies produce generic chloroxine formulations. Examples include companies specializing in OTC and prescription dermatology products.
• Over-the-Counter (OTC) Brands: Brands offering acne and seborrheic dermatitis treatments containing ingredients like benzoyl peroxide, salicylic acid, and sulfur.
• Prescription Dermatology Companies: Pharmaceutical firms developing and marketing prescription topical treatments, including retinoids, topical antibiotics, and corticosteroids.

Specific companies active in the broader dermatological market, and thus indirect competitors, include:

• Galderma: Known for products like Cetaphil and Differin.
• Bausch Health Companies: Offers a range of dermatological products.
• Johnson & Johnson: Consumer health division provides acne treatments.
• Procter & Gamble: Manufactures skincare products, including those for acne.

The competitive landscape is characterized by price sensitivity and brand recognition for OTC products. For prescription markets, clinical efficacy and physician prescribing habits are key determinants.

What is the regulatory status and safety profile of chloroxine?

Chloroxine is approved by regulatory bodies for topical use in specific indications. In the United States, the Food and Drug Administration (FDA) has approved chloroxine in prescription topical formulations for seborrheic dermatitis of the scalp. Its use in acne treatment is primarily within OTC products, where it is regulated as a drug.

Safety Profile: Chloroxine generally has a favorable safety profile when used topically as directed. Common side effects are usually mild and may include:

• Skin irritation
• Redness
• Dryness
• Burning sensation

More severe adverse effects are rare. It is important to note that systemic absorption of chloroxine from topical application is minimal. However, as with any pharmaceutical, potential risks exist, and professional medical advice should be sought.

The regulatory landscape is stable for its existing approved uses. Any expansion into new indications or novel formulations would require further regulatory review and approval processes.

What are the manufacturing and supply chain considerations for chloroxine?

The manufacturing of chloroxine, as a well-established chemical entity, is generally straightforward. The synthesis process is known and does not typically involve highly complex or proprietary steps, allowing for efficient production by multiple manufacturers.

Manufacturing:

• Active Pharmaceutical Ingredient (API) Production: API manufacturers operate in a competitive environment with established synthesis routes. Quality control and adherence to Good Manufacturing Practices (GMP) are critical.
• Formulation: Chloroxine is formulated into various topical products, including shampoos, creams, lotions, and foams. This stage requires expertise in cosmetic and pharmaceutical formulation to ensure stability, efficacy, and patient acceptability.

Supply Chain: The supply chain for chloroxine is relatively mature.

• Raw Material Sourcing: Key raw materials for chloroxine synthesis are generally available from multiple suppliers.
• Distribution: Finished products are distributed through pharmaceutical wholesalers and directly to retail pharmacies and healthcare providers.
• Global Reach: Chloroxine-containing products are available globally, with varying regulatory approvals and market penetration depending on the region.

Challenges in the supply chain can arise from:

• Quality Control: Maintaining consistent API quality across different manufacturers.
• Regulatory Compliance: Ensuring adherence to GMP and regional drug registration requirements.
• Competition: Price pressures among generic manufacturers can impact margins.

What is the investment outlook for chloroxine?

The investment outlook for chloroxine is characterized by its position as a mature, generic drug. This segment of the pharmaceutical market typically offers stable, albeit modest, returns.

Strengths for Investment:

• Established Efficacy and Safety: Long history of use and a well-understood safety profile reduce clinical development risk.
• Cost-Effectiveness: Low manufacturing cost and availability of generic versions make it an affordable treatment option.
• Consistent Demand: Chronic dermatological conditions like seborrheic dermatitis and acne ensure ongoing demand.
• OTC Market Potential: Significant opportunity in the over-the-counter segment for accessible skin treatments.

Weaknesses and Risks:

• Limited Growth Potential: The absence of strong patent protection and crowded market limit opportunities for significant market share expansion or price increases.
• Intense Competition: Price wars and competition from newer, more advanced treatments can erode profit margins.
• Innovation Lag: Without new patents or novel formulations, reinvestment in R&D for chloroxine itself is unlikely to yield substantial returns.
• Therapeutic Stagnation: The drug's core applications are well-established; breakthroughs for new, high-value indications are improbable without significant new research.

Investment Strategy: Investment in chloroxine is best suited for entities focused on:

• Generic Manufacturing: Companies with efficient manufacturing processes and strong distribution networks can achieve profitability through volume.
• Niche Topical Formulations: Developing improved or differentiated topical formulations (e.g., enhanced delivery, combination products) with limited IP protection could create niche markets.
• Emerging Markets: Focusing on regions where cost-effective treatments are prioritized.

An investment scenario would likely involve acquiring or developing manufacturing capabilities for generic chloroxine or identifying opportunities for specific, well-defined formulation improvements that offer marginal benefits over existing generic products. Significant capital investment for new drug development based solely on chloroxine's core API is not advisable due to the lack of patent protection.

Key Takeaways

Chloroxine is a mature antiparasitic and antiseptic agent with an expired foundational patent landscape. Its market is driven by topical dermatological applications, primarily acne and seborrheic dermatitis. The market is characterized by generic competition, price sensitivity, and moderate growth potential tied to the broader dermatological sector. Investment is most viable for generic manufacturers or those developing niche formulations, rather than for R&D of the core compound.

FAQs

1. Are there any active patents protecting novel uses of chloroxine? While foundational patents have expired, there is a possibility of active secondary patents covering specific novel formulations, delivery systems, or unique therapeutic applications. These would require detailed patent landscape analysis to identify.

2. What are the primary regulatory hurdles for a company looking to market a chloroxine-based product? Companies must adhere to Good Manufacturing Practices (GMP) for API and finished product manufacturing, obtain relevant drug registrations (e.g., FDA approval for prescription products, monograph compliance for OTC drugs), and meet labeling and packaging requirements specific to their target markets.

3. Can chloroxine be effectively combined with other dermatological active ingredients? Yes, chloroxine can be formulated into combination products. However, any such combination would require rigorous stability, compatibility, and efficacy testing, and any novel combination formulation could be eligible for new patent protection.

4. What is the typical profit margin for generic chloroxine products? Profit margins for generic chloroxine products are generally modest and highly dependent on manufacturing efficiency, market competition, and sales volume. They are typically lower than those for patented, novel drugs.

5. What are the key risks associated with investing in the chloroxine market? Key risks include intense price competition from numerous generic manufacturers, the lack of significant growth potential due to expired patents, and competition from newer, more advanced dermatological treatments that may offer superior efficacy or patient experience.

Citations

[1] Market Research Future. (2023). Acne Treatment Market: Global Forecast till 2030. Retrieved from [Data publicly available through market research reports; specific URL for proprietary report not provided here].